Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta …
M Thulliez, D Angoulvant, ML Le Lez… - JAMA …, 2014 - jamanetwork.com
Importance Few data exist regarding the systemic safety of intravitreal antivascular
endothelial growth factor (anti-VEGF) monoclonal antibody (mAb). Objective To conduct a
systematic review and meta-analysis to evaluate the risk of major cardiovascular and
nonocular hemorrhagic events in patients with neovascular age-related macular
degeneration (AMD), diabetes mellitus–associated macular edema (DME), or retinal vein
occlusions (RVOs) who receive intravitreal anti-VEGF mAbs. Data Sources The MEDLINE …
endothelial growth factor (anti-VEGF) monoclonal antibody (mAb). Objective To conduct a
systematic review and meta-analysis to evaluate the risk of major cardiovascular and
nonocular hemorrhagic events in patients with neovascular age-related macular
degeneration (AMD), diabetes mellitus–associated macular edema (DME), or retinal vein
occlusions (RVOs) who receive intravitreal anti-VEGF mAbs. Data Sources The MEDLINE …